The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.
Sitravatinib (MGCD516) and Nivolumab in Oral cavity cancer Window opportunity study (SNOW)Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
Principal Investigator: Lillian Siu
Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO)Eligible Tumour Type(s): Breast Cancer, Colorectal Cancer, Fallopian Tube Tumours, Malignant Pleural Mesothelioma, Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Squamous Cell Carcinoma of the Oral Cavity, Triple Negative Breast Cancer
Principal Investigator: Lillian Siu & Anna Spreafico(Second PI)
Tumor Immunotherapy and MicrobiomE Analysis Project (TIME)Eligible Tumour Type(s): Metastatic Melanoma
Principal Investigator: Marcus Butler